NHS England has announced that hundreds of babies have begun to be tested for over 200 genetic conditions as part of a study led by Genomics England. The Generation Study is evaluating the potential ...

Moorfields Pharmaceuticals is the manufacturing arm of Moorfields Eye Hospital NHS Foundation Trust. We produce nearly 100 ophthalmic specials and have a growing portfolio of branded licensed products ...

The fourth annual QiC Dermatology Awards took place in Reading earlier this month and results can be found online here: QiC ...

Highly encouraged to read this in Jim Nantz voice Hello friends. Consider a brand. Picture an experience. The Masters, one of ...

Eli Lilly and Almirall have announced positive long-term results for their targeted IL-13 inhibitor Ebglyss ...

Sanofi and Regeneron’s Dupixent (dupilumab) has been recommended by the European Medicines Agency’s human medicines committee to treat younger eosinophilic oesophagitis (EoE) patients. The Committee ...

The US Food and Drug Administration (FDA) has approved Zevra Therapeutics’ Miplyffa (arimoclomol) to treat Niemann-Pick disease type C (NPC), an ultra-rare lysosomal storage disorder affecting one in ...

Ipsen’s Iqirvo (elafibranor) has been conditionally approved by the European Commission (EC) to treat primary biliary cholangitis (PBC). The oral peroxisome proliferator-activated receptor (PPAR) ...

Risk taking is complicated. In business, ebullient entrepreneurs are lauded for putting their livelihood on the line and taking risks, while serial gamblers who do the same are frowned upon. When it ...

The marketeer wants the agency it knows and trusts, not the ones on the list; the agency has spent a fortune on a pitch only to find the budget is a fraction of that suggested and the plan has changed ...

Wedgewood Communications has appointed Danielle Cranwell as president and global agency head to lead the evolution of the agency’s strategic vision and future direction. Cranwell brings more than two ...

Merck & Co – known as MSD outside the US and Canada – has shared positive overall survival (OS) results from a late-stage study of its Keytruda (pembrolizumab) regimen in early-stage breast cancer.